Various preclinical studies and ongoing clinical trials aimed to evaluate the efficiency of CD38 antibodies in hematological malignancies such as NK/T cell lymphoma and acute lymphoblastic leukemia [27, 28]. This evidence concerns the gene CD38 and hematologic disorder.